The Association Between Different Monocyte Subsets and Coronary Collateral Development

Sponsor

Yuksek Ihtisas Hospital (Other)

Overall Status

Completed

CT.gov ID

NCT01356836

Collaborator

(none)

105

Enrollment

Location

3.9

Duration (Months)

26.6

Patients Per Site Per Month

Study Details

Study Description

Brief Summary

Collateral growth and coronary angiogenesis are chronic adaptations to myocardial ischemia. Collateralization helps to restore blood flow and as a result salvages myocardium in severely ischemic myocardial regions. Thus, good collateral development in patients with severe coronary artery disease (CAD) improves ventricular function and prognosis (1-3).

However, coronary collateral development is different among patients even with similar degrees of coronary artery stenosis. Several factors, such as diabetes mellitus (4) and duration of myocardial ischemic symptoms (5) have been reported to effect coronary collateral development. At the cellular level, inflammatory cells, especially monocytes have an important role in collateralization. In a series of experimental studies with animals, it has been shown that monocytes are important elements for development of collateral vessels (6-7). In a recent study, it has been demonstrated that increased circulating monocyte count is related to good collateral development in patients with stable coronary artery disease (8).

Monocytes in human blood are heterogeneous and can be classified into two subsets according to the presence or absence of the FcγRIII receptor CD16 (9): CD14++CD16- monocytes characterized by high level expression of the CD14 cell surface receptor but no expression of CD16 receptor, and CD14+CD16+ monocytes characterized by the co-expression of CD16 receptor with either high or low level expression of the CD14 receptor. These subsets differ in function and response to several cytokines.

Our aim in this study was to find out any possible relationship between the levels of circulating monocyte subsets and coronary collateral development.

Condition or Disease	Intervention/Treatment	Phase
Coronary Artery Disease Coronary Ischemia

Study Design

Study Type:

Observational

Actual Enrollment :

105 participants

Observational Model:

Cohort

Time Perspective:

Prospective

Study Start Date :

Jan 1, 2011

Actual Primary Completion Date :

May 1, 2011

Actual Study Completion Date :

May 1, 2011

Arms and Interventions

Arm	Intervention/Treatment
Good-poor collateral Patients who had good and poor collaterals formed 2 groups
Good collateral, Poor collateral

Outcome Measures

Primary Outcome Measures

Eligibility Criteria

Criteria

Ages Eligible for Study:

18 Years to 80 Years

Sexes Eligible for Study:

All

Accepts Healthy Volunteers:

Inclusion Criteria:

95% stenosis of at least one major coronary artery in their first coronary angiogram

Exclusion Criteria:

previous percutaneous or surgical revascularization history
evidence of ongoing infection and inflammation
known malignancy and chronic kidney disease (serum creatinine > 1.5 mg/dl
diabetic patients

Contacts and Locations

Locations

	Site	City	State	Country	Postal Code
1	1Türkiye Yüksek İhtisas Education and Research Hospital, Department of Cardiology	Ankara		Turkey	06550

Sponsors and Collaborators

Yuksek Ihtisas Hospital

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.

Responsible Party:

, ,

ClinicalTrials.gov Identifier:

NCT01356836

Other Study ID Numbers:

Monocyte subsets

First Posted:

May 20, 2011

Last Update Posted:

May 20, 2011

Last Verified:

Mar 1, 2011

Keywords provided by , ,

Coronary collateral development

monocyte subsets

collateralization

Additional relevant MeSH terms:

Coronary Artery Disease

Ischemia

Study Results

No Results Posted as of May 20, 2011